Pharmacokinetics and Tolerability Study of Risperidone ISM® in Schizophrenia
Status:
Completed
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
To characterize the pharmacokinetics (PK) of the injectable intramuscular (IM) long-acting
formulation (in situ microparticle, ISM) of risperidone over four IM injections in the
gluteal and deltoid muscle at 28-day intervals and at one dose strength (75 mg) in patients
with schizophrenia.